Browse TAP1

Summary
SymbolTAP1
Nametransporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Aliases RING4; D6S114E; ABCB2; ABC17; PSF-1; RING4*0102N; TAP1N; ABC transporter, MHC 1; ATP-binding cassette sub-fa ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane; Multi-pass membrane protein. Note=The transmembrane segments seem to form a pore in the membrane.
Domain PF00664 ABC transporter transmembrane region
PF00005 ABC transporter
Function

Involved in the transport of antigens from the cytoplasm to the endoplasmic reticulum for association with MHC class I molecules. Also acts as a molecular scaffold for the final stage of MHC class I folding, namely the binding of peptide. Nascent MHC class I molecules associate with TAP via tapasin. Inhibited by the covalent attachment of herpes simplex virus ICP47 protein, which blocks the peptide-binding site of TAP. Inhibited by human cytomegalovirus US6 glycoprotein, which binds to the lumenal side of the TAP complex and inhibits peptide translocation by specifically blocking ATP-binding to TAP1 and prevents the conformational rearrangement of TAP induced by peptide binding. Inhibited by human adenovirus E3-19K glycoprotein, which binds the TAP complex and acts as a tapasin inhibitor, preventing MHC class I/TAP association. Expression of TAP1 is down-regulated by human Epstein-Barr virus vIL-10 protein, thereby affecting the transport of peptides into the endoplasmic reticulum and subsequent peptide loading by MHC class I molecules.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002428 antigen processing and presentation of peptide antigen via MHC class Ib
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I
GO:0002475 antigen processing and presentation via MHC class Ib
GO:0002476 antigen processing and presentation of endogenous peptide antigen via MHC class Ib
GO:0002477 antigen processing and presentation of exogenous peptide antigen via MHC class Ib
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002481 antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent
GO:0002483 antigen processing and presentation of endogenous peptide antigen
GO:0002484 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway
GO:0002485 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent
GO:0002488 antigen processing and presentation of endogenous peptide antigen via MHC class Ib via ER pathway
GO:0002489 antigen processing and presentation of endogenous peptide antigen via MHC class Ib via ER pathway, TAP-dependent
GO:0002577 regulation of antigen processing and presentation
GO:0002579 positive regulation of antigen processing and presentation
GO:0002583 regulation of antigen processing and presentation of peptide antigen
GO:0002585 positive regulation of antigen processing and presentation of peptide antigen
GO:0002589 regulation of antigen processing and presentation of peptide antigen via MHC class I
GO:0002591 positive regulation of antigen processing and presentation of peptide antigen via MHC class I
GO:0015833 peptide transport
GO:0019058 viral life cycle
GO:0019060 intracellular transport of viral protein in host cell
GO:0019882 antigen processing and presentation
GO:0019883 antigen processing and presentation of endogenous antigen
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0019885 antigen processing and presentation of endogenous peptide antigen via MHC class I
GO:0030581 symbiont intracellular protein transport in host
GO:0042886 amide transport
GO:0043900 regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044766 multi-organism transport
GO:0046719 regulation by virus of viral protein levels in host cell
GO:0046794 transport of virus
GO:0046967 cytosol to ER transport
GO:0048002 antigen processing and presentation of peptide antigen
GO:0050792 regulation of viral process
GO:0051701 interaction with host
GO:0051708 intracellular protein transport in other organism involved in symbiotic interaction
GO:0075733 intracellular transport of virus
GO:1902579 multi-organism localization
GO:1902581 multi-organism cellular localization
GO:1902583 multi-organism intracellular transport
Molecular Function GO:0003823 antigen binding
GO:0015197 peptide transporter activity
GO:0015399 primary active transmembrane transporter activity
GO:0015405 P-P-bond-hydrolysis-driven transmembrane transporter activity
GO:0015433 peptide antigen-transporting ATPase activity
GO:0015440 peptide-transporting ATPase activity
GO:0016820 hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances
GO:0016887 ATPase activity
GO:0022804 active transmembrane transporter activity
GO:0023029 MHC class Ib protein binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0042287 MHC protein binding
GO:0042288 MHC class I protein binding
GO:0042605 peptide antigen binding
GO:0042623 ATPase activity, coupled
GO:0042626 ATPase activity, coupled to transmembrane movement of substances
GO:0043492 ATPase activity, coupled to movement of substances
GO:0043531 ADP binding
GO:0046977 TAP binding
GO:0046978 TAP1 binding
GO:0046979 TAP2 binding
Cellular Component GO:0018995 host
GO:0030176 integral component of endoplasmic reticulum membrane
GO:0031227 intrinsic component of endoplasmic reticulum membrane
GO:0042824 MHC class I peptide loading complex
GO:0042825 TAP complex
GO:0043657 host cell
GO:0044215 other organism
GO:0044216 other organism cell
GO:0044217 other organism part
> KEGG and Reactome Pathway
 
KEGG hsa02010 ABC transporters
hsa04145 Phagosome
hsa04612 Antigen processing and presentation
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983170: Antigen Presentation
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1236974: ER-Phagosome pathway
R-HSA-168256: Immune System
Summary
SymbolTAP1
Nametransporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Aliases RING4; D6S114E; ABCB2; ABC17; PSF-1; RING4*0102N; TAP1N; ABC transporter, MHC 1; ATP-binding cassette sub-fa ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TAP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TAP1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29341428Breast CarcinomaPromote immunity (T cell function)Gene expression analysis of the sorted tumor cells revealed that the Aldefluor+ tumor cells has decreased expression of transporter associated with antigen processing (TAP) genes and co-stimulatory molecule CD80, which would decrease susceptibility to T cells.
16517708Head and Neck Squamous Cell CarcinomaPromote immunity (T cell function)First, lack of recognition of SCCHN cells by CTL is associated with marked down-regulation of the IFN-gamma-inducible APM components low-m.w. protein 2, TAP1, TAP2, and tapasin.
28783722MelanomaPromote immunity (T cell function); essential for immunotherapyWe observed that the reduction in the overall survival of these patients was significantly associated with loss of expression of B2M and TAP1 in tumours biopsied before ipilimumab treatment. Loss of expression of these 19 genes within tumours could diminish or extinguish the presentation of tumour antigens (including HLA-A, HLA-F, B2M, TAP1 and TAP2); T cell co- stimulation (ICAM1, CLECL1, LILRA1 and LILRA3); or cytokine production and signalling (JAK2 and STAT1) in the tumour microenvironment that drive infiltration and activation of T cells, and thus serve as a principal mechanism in immune evasion.
27496866Head and Neck CarcinomaPromote immunity (T cell function); essential for immunotherapyCD137 agonist mAb urelumab enhanced cetuximab-activated NK-cell survival, DC maturation, and tumor antigen cross-presentation. Urelumab boosted DC maturation markers, CD86 and HLA DR, and antigen-processing machinery (APM) components TAP1/2, leading to increased tumor antigen cross-presentation. These results suggest a beneficial effect of combination immunotherapy using cetuximab and CD137 agonist in HNC.
18519766Ovarian CancinomaPromote immunity (infiltration)The majority of APM component expression examined was significantly associated with both intratumoral and peritumoral T-cell infiltration (P < 0.05). The expression of APM components and the presence of intratumoral T-cell infiltrates were significantly associated with improved survival (all P < or = 0.01);
17541610AstrocytomaPromote immunityAmong human WHO grade II-IV astrocytomas, downregulation of LMP2, TAP1 and beta2m correlated with grade of malignancy. Our results support the hypothesis that coordinated downregulation or impaired upregulation of certain HLA class I APM components may serve as a mechanism for astrocytoma cells to evade the host's immune response, even if HLA class I antigen surface expression is not altered.
16140964Lung CarcinomaPromote immunityFluorescence-activated cell sorting and ELISPOT analysis showed that AdhTAP1 treatment significantly increased dendritic cell cross-presentation and cross-priming of tumor antigens. Furthermore, ex vivo and in vivo AdhTAP1 treatment significantly retarded tumor growth and increased survival of mice bearing CMT.64 tumors. Fluorescence-activated cell sorting analysis and immunohistochemical staining showed a significant increase in CD8+ and CD4+ T cells and CD11c+ dendritic cells infiltrating the tumors.
Summary
SymbolTAP1
Nametransporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Aliases RING4; D6S114E; ABCB2; ABC17; PSF-1; RING4*0102N; TAP1N; ABC transporter, MHC 1; ATP-binding cassette sub-fa ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TAP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 2.55; FDR: 0.000150 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 1.05 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 6.00; FDR: 0.000 Resistant to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 6.41; FDR: 0.001 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 2 Resistant to T-cell proliferation
Summary
SymbolTAP1
Nametransporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Aliases RING4; D6S114E; ABCB2; ABC17; PSF-1; RING4*0102N; TAP1N; ABC transporter, MHC 1; ATP-binding cassette sub-fa ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TAP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3120.431
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4790.732
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1890.863
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.0540.0241
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.1670.625
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9180.775
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.770.142
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1590.514
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2640.9
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3110.561
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0330.768
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4120.0153
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TAP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 1113015.4-15.40.482
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512016.7-16.71
Summary
SymbolTAP1
Nametransporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Aliases RING4; D6S114E; ABCB2; ABC17; PSF-1; RING4*0102N; TAP1N; ABC transporter, MHC 1; ATP-binding cassette sub-fa ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TAP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTAP1
Nametransporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Aliases RING4; D6S114E; ABCB2; ABC17; PSF-1; RING4*0102N; TAP1N; ABC transporter, MHC 1; ATP-binding cassette sub-fa ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TAP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TAP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTAP1
Nametransporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Aliases RING4; D6S114E; ABCB2; ABC17; PSF-1; RING4*0102N; TAP1N; ABC transporter, MHC 1; ATP-binding cassette sub-fa ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TAP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTAP1
Nametransporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Aliases RING4; D6S114E; ABCB2; ABC17; PSF-1; RING4*0102N; TAP1N; ABC transporter, MHC 1; ATP-binding cassette sub-fa ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TAP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTAP1
Nametransporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Aliases RING4; D6S114E; ABCB2; ABC17; PSF-1; RING4*0102N; TAP1N; ABC transporter, MHC 1; ATP-binding cassette sub-fa ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TAP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTAP1
Nametransporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Aliases RING4; D6S114E; ABCB2; ABC17; PSF-1; RING4*0102N; TAP1N; ABC transporter, MHC 1; ATP-binding cassette sub-fa ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TAP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.